Your browser doesn't support javascript.
loading
[Relapsed primary central nervous system lymphoma treated with CD19 chimeric antigen receptor T-cell therapy and allogeneic hematopoietic stem cell transplantation].
Fujii, Fuminari; Terao, Toshiki; Nishimori, Hisakazu; Fujii, Kentaro; Matsuo, Toshihiko; Yoshino, Tadashi; Ueda, Hiroko; Oyama, Tadashi; Matsumura, Akifumi; Kondo, Kaho; Matsubara, Chisato; Fujiwara, Kanako; Seike, Keisuke; Fujiwara, Hideaki; Asada, Noboru; Ennishi, Daisuke; Fujii, Keiko; Fujii, Nobuharu; Matsuoka, Ken-Ichi; Maeda, Yoshinobu.
Afiliación
  • Fujii F; Center for Graduate Medical Education, Okayama University Hospital.
  • Terao T; Department of Hematology and Oncology, Okayama University Hospital.
  • Nishimori H; Department of Hematology and Oncology, Okayama University Hospital.
  • Fujii K; Department of Hematology and Oncology, Okayama University Hospital.
  • Matsuo T; Department of Hematology, Hiroshima City Hiroshima Citizens Hospital.
  • Yoshino T; Department of Neurological Surgery, Okayama University Hospital.
  • Ueda H; Department of Ophthalmology, Okayama University Hospital.
  • Oyama T; Department of Pathology, Okayama University Hospital.
  • Matsumura A; Department of Hematology and Oncology, Okayama University Hospital.
  • Kondo K; Department of Hematology and Oncology, Okayama University Hospital.
  • Matsubara C; Department of Hematology and Oncology, Okayama University Hospital.
  • Fujiwara K; Department of Hematology and Oncology, Okayama University Hospital.
  • Seike K; Department of Hematology and Oncology, Okayama University Hospital.
  • Fujiwara H; Department of Hematology and Oncology, Okayama University Hospital.
  • Asada N; Department of Hematology and Oncology, Okayama University Hospital.
  • Ennishi D; Department of Hematology and Oncology, Okayama University Hospital.
  • Fujii K; Department of Hematology and Oncology, Okayama University Hospital.
  • Fujii N; Department of Hematology and Oncology, Okayama University Hospital.
  • Matsuoka KI; Department of Hematology and Oncology, Okayama University Hospital.
  • Maeda Y; Division of Clinical Laboratory, Okayama University Hospital.
Rinsho Ketsueki ; 65(7): 622-627, 2024.
Article en Ja | MEDLINE | ID: mdl-39098011
ABSTRACT
Relapsed and/or refractory (R/R) primary central nervous system lymphoma (PCNSL) has a poor prognosis. A 57-year-old man diagnosed with PCNSL achieved a complete response by high-dose methotrexate-based chemotherapy followed by autologous hematopoietic stem cell transplantation (ASCT). The disease was not cured, so he was treated with the anti-CD19 chimeric antigen receptor (CAR) T-cell therapy tisagenlecleucel after the third relapse. However, the disease relapsed again 28 days after CAR T-cell therapy. Allogeneic hematopoietic stem cell transplantation (allo-HSCT) was attempted as curative therapy after bridging with second ASCT and tirabrutinib monotherapy. Although a temporary response was achieved, the disease relapsed 98 days after allo-HSCT. While receiving tirabrutinib for relapse after allo-HSCT, the patient developed acute respiratory failure due to transplant-related toxicity and post-transplant thrombotic microangiopathy. He died 175 days after allo-HSCT. Although various treatments for PCNSL have been investigated in recent years, the treatment strategy for R/R PCNSL has not been established. Further studies are warranted to improve the outcomes of patients with R/R PCNSL.
Asunto(s)
Palabras clave
Texto completo
Añadir a Mi BVS
Imprimir
XML
PubMed Links
Buscar en Google

Texto completo: 1 Colección: 01-internacional Base de datos: MEDLINE Asunto principal: Recurrencia / Trasplante Homólogo / Neoplasias del Sistema Nervioso Central / Trasplante de Células Madre Hematopoyéticas Límite: Humans / Male / Middle aged Idioma: Ja Revista: Rinsho Ketsueki Año: 2024 Tipo del documento: Article Pais de publicación: Japón
Texto completo
Añadir a Mi BVS
Imprimir
XML
PubMed Links
Buscar en Google

Texto completo: 1 Colección: 01-internacional Base de datos: MEDLINE Asunto principal: Recurrencia / Trasplante Homólogo / Neoplasias del Sistema Nervioso Central / Trasplante de Células Madre Hematopoyéticas Límite: Humans / Male / Middle aged Idioma: Ja Revista: Rinsho Ketsueki Año: 2024 Tipo del documento: Article Pais de publicación: Japón